Table 2.
Clinical characteristics of patients at diagnosis (n = 145)
| Clinical characteristics | Median (range) |
|---|---|
| Age (years) | 54 (15–83) |
| WBC (/μL) | 36 360 (2877–750 000) |
| Blast (%) | 0 (0–14) |
| Eosinophil (%) | 2.5 (0–13) |
| Basophil (%) | 5 (0–25.5) |
| Hemoglobin (g/dL) | 12.9 (4.1–16.6) |
| Platelet cells (/μL) | 48.5 (11.3–446.0) |
| LDH (/base) | 2.34 (0.76–10.28) |
| Days from diagnosis to start of treatment | 14 (0–285) |
| No. patients (%) | |
| Sex | |
| Male | 88 (60.7) |
| Female | 57 (39.3) |
| Splenomegaly (>10 cm) | |
| Yes | 36 (24.8) |
| No | 109 (75.2) |
| Range (cm) | 0–25 |
| Imatinib dose (mg) | |
| 300 | 5 (3.4) |
| 400 | 139 (95.9) |
| 600 | 1 (0.7) |
| Sokal risk | |
| Low | 66 (45.5) |
| Intermediate | 52 (35.9) |
| High | 27 (18.6) |
| Hasford risk | |
| Low | 60 (41.4) |
| Intermediate | 72 (49.6) |
| High | 13 (9.0) |
| EUTOS risk | |
| Low | 129 (89.0) |
| High | 16 (11.0) |
EUTOS, European Treatment and Outcome Study; LDH, lactate dehydrogenase; WBC, white blood cell.